135 related articles for article (PubMed ID: 10536419)
1. [Macrophage-colony stimulating factor and ovarian cancer].
Menditto A; Piscittelli V; Cassese F; Balbi GC; Balbi C; Cardone A
Minerva Ginecol; 1999; 51(7-8):261-4. PubMed ID: 10536419
[TBL] [Abstract][Full Text] [Related]
2. Macrophage colony-stimulating factor as a tumor marker for epithelial ovarian cancer.
Suzuki M; Ohwada M; Aida I; Tamada T; Hanamura T; Nagatomo M
Obstet Gynecol; 1993 Dec; 82(6):946-50. PubMed ID: 8233270
[TBL] [Abstract][Full Text] [Related]
3. [The plasma levels and diagnostic utility of granulocyte colony stimulating factor (G-CSF) and macrophage - colony stimulating factor (M-CSF) in ovarian cancer patients].
ławicki S; Czygier M; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2006 Nov; 21(125):465-8. PubMed ID: 17345841
[TBL] [Abstract][Full Text] [Related]
4. Clinical significance of combined use of macrophage colony-stimulating factor and squamous cell carcinoma antigen as a selective diagnostic marker for squamous cell carcinoma arising in mature cystic teratoma of the ovary.
Suzuki M; Tamura N; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 2000 Jun; 77(3):405-9. PubMed ID: 10831350
[TBL] [Abstract][Full Text] [Related]
5. Serum macrophage-colony stimulating factor levels in colorectal cancer patients correlate with lymph node metastasis and poor prognosis.
Mroczko B; Groblewska M; Wereszczyńska-Siemiatkowska U; Okulczyk B; Kedra B; Łaszewicz W; Dabrowski A; Szmitkowski M
Clin Chim Acta; 2007 May; 380(1-2):208-12. PubMed ID: 17368603
[TBL] [Abstract][Full Text] [Related]
6. The pretreatment plasma level and diagnostic utility of M-CSF in benign breast tumor and breast cancer patients.
Ławicki S; Szmitkowski M; Wojtukiewicz M
Clin Chim Acta; 2006 Sep; 371(1-2):112-6. PubMed ID: 16631152
[TBL] [Abstract][Full Text] [Related]
7. The role of colony-stimulating factor 1 and its receptor in the etiopathogenesis of endometrial adenocarcinoma.
Smith HO; Anderson PS; Kuo DY; Goldberg GL; DeVictoria CL; Boocock CA; Jones JG; Runowicz CD; Stanley ER; Pollard JW
Clin Cancer Res; 1995 Mar; 1(3):313-25. PubMed ID: 9815987
[TBL] [Abstract][Full Text] [Related]
8. Macrophage colony-stimulating factor as a marker for malignant germ cell tumors of the ovary.
Suzuki M; Kobayashi H; Ohwada M; Terao T; Sato I
Gynecol Oncol; 1998 Jan; 68(1):35-7. PubMed ID: 9454657
[TBL] [Abstract][Full Text] [Related]
9. Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer.
Gadducci A; Ferdeghini M; Castellani C; Annicchiarico C; Prontera C; Facchini V; Bianchi R; Genazzani AR
Gynecol Oncol; 1998 Jul; 70(1):111-4. PubMed ID: 9698485
[TBL] [Abstract][Full Text] [Related]
10. [The plasma levels and diagnostic utility of stem cell factor (SCF) and macrophage-colony stimulating factor (M-CSF) in cervical cancer patients].
Lawicki S; Bedkowska E; Gacuta-Szumarska E; Knapp P; Szmitkowski M
Pol Merkur Lekarski; 2008 Jul; 25(145):38-42. PubMed ID: 18839612
[TBL] [Abstract][Full Text] [Related]
11. [Selected hematopoietic cytokines in patients with colorectal cancer].
Mroczko B; Ławicki S; Szmitkowski M; Czygier M; Okulczyk B; Piotrowski Z
Pol Merkur Lekarski; 2003 Nov; 15(89):416-9. PubMed ID: 14969133
[TBL] [Abstract][Full Text] [Related]
12. [The plasma levels of granulocyte-colony stimulating factor and granulocyte-macrophage colony stimulating factor in breast cancer patients].
Ławicki S; Czygier M; Omyła J; Bedkowska E; Szmitkowski M
Pol Merkur Lekarski; 2007 Oct; 23(136):259-63. PubMed ID: 18293847
[TBL] [Abstract][Full Text] [Related]
13. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
14. [Study on serum vascular endothelial growth factor level in ovarian malignant tumors].
Li L; Wang LM; Zhang W; Zhang JQ; Song HL; Yao DS; Tang Y; Chen XQ; Yang ZH
Zhonghua Fu Chan Ke Za Zhi; 2003 Feb; 38(2):72-6. PubMed ID: 12783691
[TBL] [Abstract][Full Text] [Related]
15. Relationship of serum levels of tumor markers with tissue expression of gene products in ovarian carcinoma.
Sorak M; Arsenijević S; Lukić G; Arsenijević N; Ristić P; Pavlović S; Popović S; Baskić D
J BUON; 2007; 12(1):99-104. PubMed ID: 17436409
[TBL] [Abstract][Full Text] [Related]
16. Is there a correlation between tumor marker panel and tumor size and histopathology in well staged patients with borderline ovarian tumors?
Ayhan A; Guven S; Guven ES; Kucukali T
Acta Obstet Gynecol Scand; 2007; 86(4):484-90. PubMed ID: 17486473
[TBL] [Abstract][Full Text] [Related]
17. Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors.
Engelen MJ; de Bruijn HW; Hollema H; ten Hoor KA; Willemse PH; Aalders JG; van der Zee AG
Gynecol Oncol; 2000 Jul; 78(1):16-20. PubMed ID: 10873403
[TBL] [Abstract][Full Text] [Related]
18. Angiogenin, interleukins, and growth-factor levels in serum of patients with ovarian cancer: correlation with angiogenesis.
Chopra V; Dinh TV; Hannigan EV
Cancer J Sci Am; 1996; 2(5):279-85. PubMed ID: 9166545
[TBL] [Abstract][Full Text] [Related]
19. Clinical usefulness of macrophage colony-stimulating factor for ovarian cancers: Long-term prognosis after five years.
Mizutani K; Takeuchi S; Ohashi Y; Yakushiji M; Nishimura H; Takahashi T; Maruhashi T; Ueda K; Noda K; Watanabe Y; Kawana T; Terashima Y; Ochiai K; Goto S; Takaku F; Motoyoshi K
Oncol Rep; 2003; 10(1):127-31. PubMed ID: 12469157
[TBL] [Abstract][Full Text] [Related]
20. [Serum level and expression of vascular epithelial growth factor in ovarian epithelial carcinoma].
Sun LX; Wu Y; Han HQ; Wang QH
Ai Zheng; 2003 Jan; 22(1):58-61. PubMed ID: 12561438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
